Page last updated: 2024-10-16

adenine and Joint Pain

adenine has been researched along with Joint Pain in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	2 (40.00)	2.80

Authors

Authors	Studies
Siddiqi, T	1
Coutre, S	1
McKinney, M	1
Barr, PM	1
Rogers, K	1
Mokatrin, A	1
Valentino, R	1
Szoke, A	1
Deshpande, S	1
Zhu, A	1
Arango-Hisijara, I	1
Osei-Bonsu, K	1
Wang, M	1
O'Brien, S	1
Lipsky, A	1
Lamanna, N	1
Gribben, JG	1
Bosch, F	1
Cymbalista, F	1
Geisler, CH	1
Ghia, P	1
Hillmen, P	1
Moreno, C	1
Stilgenbauer, S	1
Stephens, DM	1
Byrd, JC	1
Sax, PE	1
Wohl, D	1
Yin, MT	1
Post, F	1
DeJesus, E	1
Saag, M	1
Pozniak, A	1
Thompson, M	1
Podzamczer, D	1
Molina, JM	1
Oka, S	1
Koenig, E	1
Trottier, B	1
Andrade-Villanueva, J	1
Crofoot, G	1
Custodio, JM	1
Plummer, A	1
Zhong, L	1
Cao, H	1
Martin, H	1
Callebaut, C	1
Cheng, AK	1
Fordyce, MW	1
McCallister, S	1

Clinical Trials (3)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Trea[NCT01780506]	Phase 3	872 participants (Actual)	Interventional	2012-12-26	Completed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treat[NCT01797445]	Phase 3	872 participants (Actual)	Interventional	2013-03-12	Completed
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994]		275 participants (Actual)	Observational [Patient Registry]	2018-02-06	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in CD4+ Cell Count at Week 144

(NCT01780506)
Timeframe: Baseline; Week 144

Intervention	cells/µL (Mean)
E/C/F/TAF	323
E/C/F/TDF	310

Change From Baseline in CD4+ Cell Count at Week 48

(NCT01780506)
Timeframe: Baseline; Week 48

Intervention	cells/µL (Mean)
E/C/F/TAF	235
E/C/F/TDF	221

Change From Baseline in CD4+ Cell Count at Week 96

(NCT01780506)
Timeframe: Baseline; Week 96

Intervention	cells/µL (Mean)
E/C/F/TAF	285
E/C/F/TDF	271

Change From Baseline in Serum Creatinine at Week 144

(NCT01780506)
Timeframe: Baseline; Week 144

Intervention	mg/dL (Mean)
E/C/F/TAF	0.04
E/C/F/TDF	0.08

Change From Baseline in Serum Creatinine at Week 48

(NCT01780506)
Timeframe: Baseline; Week 48

Intervention	mg/dL (Mean)
E/C/F/TAF	0.08
E/C/F/TDF	0.11

Change From Baseline in Serum Creatinine at Week 96

(NCT01780506)
Timeframe: Baseline; Week 96

Intervention	mg/dL (Mean)
E/C/F/TAF	0.05
E/C/F/TDF	0.07

Percent Change From Baseline in Hip BMD at Week 144

Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144

Intervention	percent change (Mean)
E/C/F/TAF	-0.826
E/C/F/TDF	-3.475

Percent Change From Baseline in Hip BMD at Week 96

Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96

Intervention	percent change (Mean)
E/C/F/TAF	-0.951
E/C/F/TDF	-3.515

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01780506)
Timeframe: Baseline; Week 48

Intervention	percent change (Mean)
E/C/F/TAF	-0.865
E/C/F/TDF	-3.200

Percent Change From Baseline in Spine BMD at Week 144

Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144

Intervention	percent change (Mean)
E/C/F/TAF	-0.809
E/C/F/TDF	-3.023

Percent Change From Baseline in Spine BMD at Week 48

Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 48

Intervention	percent change (Mean)
E/C/F/TAF	-1.337
E/C/F/TDF	-2.956

Percent Change From Baseline in Spine BMD at Week 96

Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96

Intervention	percent change (Mean)
E/C/F/TAF	-0.907
E/C/F/TDF	-3.053

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 144

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144

Intervention	percent change (Median)
E/C/F/TAF	-24.6
E/C/F/TDF	60.4

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48

Intervention	percent change (Median)
E/C/F/TAF	-32.8
E/C/F/TDF	18.0

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96

Intervention	percent change (Median)
E/C/F/TAF	-33.5
E/C/F/TDF	32.5

Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 144

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144

Intervention	percent change (Median)
E/C/F/TAF	37.4
E/C/F/TDF	106.9

Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96

Intervention	percent change (Median)
E/C/F/TAF	11.3
E/C/F/TDF	75.0

Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48

Intervention	percent change (Median)
E/C/F/TAF	6.9
E/C/F/TDF	51.2

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Week 48

Intervention	percentage of participants (Number)
E/C/F/TAF	93.1
E/C/F/TDF	92.8

Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 144

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 144 weeks

Intervention	percentage of participants (Number)
	Grade 1	Grade 2	Grade 3
E/C/F/TAF	31.3	6.0	0.2
E/C/F/TDF	37.1	7.0	0.2

Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 48

Intervention	percentage of participants (Number)
	Grade 1	Grade 2	Grade 3
E/C/F/TAF	25.8	4.6	0
E/C/F/TDF	32.3	4.9	0.2

Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 96

Intervention	percentage of participants (Number)
	Grade 1	Grade 2	Grade 3
E/C/F/TAF	28.8	5.1	0.2
E/C/F/TDF	33.9	5.8	0.2

Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48, 96, and 144

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48, 96, and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 48, 96. and 144

Intervention	percentage of participants (Number)
	Week 48	Week 96	Week 144
E/C/F/TAF	86.4	84.4	84.6
E/C/F/TDF	87.3	83.6	80.1

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 96 and 144

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Weeks 96 and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 96 and 144

Intervention	percentage of participants (Number)
	Week 96	Week 144
E/C/F/TAF	89.2	86.9
E/C/F/TDF	88.2	83.1

Change From Baseline in CD4+ Cell Count at Week 48

(NCT01797445)
Timeframe: Baseline; Week 48

Intervention	cells/µL (Mean)
E/C/F/TAF	225
E/C/F/TDF	200

Change From Baseline in CD4+ Cell Count at Week 96

(NCT01797445)
Timeframe: Baseline; Week 96

Intervention	cells/µL (Mean)
E/C/F/TAF	274
E/C/F/TDF	260

Change From Baseline in Serum Creatinine at Week 48

(NCT01797445)
Timeframe: Baseline; Week 48

Intervention	mg/dL (Mean)
E/C/F/TAF	0.08
E/C/F/TDF	0.12

Change From Baseline in Serum Creatinine at Week 96

(NCT01797445)
Timeframe: Baseline; Week 96

Intervention	mg/dL (Mean)
E/C/F/TAF	0.04
E/C/F/TDF	0.07

Percent Change From Baseline in Hip BMD at Week 96

Hip BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96

Intervention	percent change (Mean)
E/C/F/TAF	-0.364
E/C/F/TDF	-3.023

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01797445)
Timeframe: Baseline; Week 48

Intervention	percent change (Mean)
E/C/F/TAF	-0.420
E/C/F/TDF	-2.603

Percent Change From Baseline in Spine BMD at Week 48

Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 48

Intervention	percent change (Mean)
E/C/F/TAF	-1.278
E/C/F/TDF	-2.759

Percent Change From Baseline in Spine BMD at Week 96

Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96

Intervention	percent change (Mean)
E/C/F/TAF	-1.017
E/C/F/TDF	-2.516

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48

Intervention	percent change (Median)
E/C/F/TAF	-29.3
E/C/F/TDF	32.3

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96

Intervention	percent change (Median)
E/C/F/TAF	-31.0
E/C/F/TDF	35.2

Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96

Intervention	percent change (Median)
E/C/F/TAF	16.9
E/C/F/TDF	73.7

Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48

Intervention	percent change (Median)
E/C/F/TAF	13.3
E/C/F/TDF	51.7

Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48

Intervention	percentage of participants (Number)
E/C/F/TAF	91.6
E/C/F/TDF	88.5

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Week 96

Intervention	percentage of participants (Number)
E/C/F/TAF	84.0
E/C/F/TDF	82.3

Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48 and 96

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48 and 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Weeks 48 and 96

Intervention	percentage of participants (Number)
	Week 48	Week 96
E/C/F/TAF	82.4	78.7
E/C/F/TDF	80.7	76.8

Percentage of Participants With Treatment-emergent Proteinuria Through Week 48

Intervention	percentage of participants (Number)
	Grade 1	Grade 2	Grade 3
E/C/F/TAF	27.3	4.7	0
E/C/F/TDF	31.6	4.6	0

Percentage of Participants With Treatment-emergent Proteinuria Through Week 96

Intervention	percentage of participants (Number)
	Grade 1	Grade 2	Grade 3
E/C/F/TAF	31.8	5.4	0
E/C/F/TDF	36.9	5.1	0

Reviews

3 reviews available for adenine and Joint Pain

Article	Year
Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology. American Society of Hematology. Education Program, 2020, 12-04, Volume: 2020, Issue:1 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Arrhythmias, Cardiac; Arthralgia; Benza	2020
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. British journal of haematology, 2018, Volume: 180, Issue:5 Topics: Adenine; Anticoagulants; Antineoplastic Agents; Arthralgia; Atrial Fibrillation; Diabetes Mellitus,	2018
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood, 2019, 03-21, Volume: 133, Issue:12 Topics: Adenine; Aged; Anti-Infective Agents; Anticoagulants; Arthralgia; Atrial Fibrillation; Drug Resistan	2019

Trials

2 trials available for adenine and Joint Pain

Article	Year
Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. Leukemia & lymphoma, 2022, Volume: 63, Issue:7 Topics: Adenine; Adult; Arthralgia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; M	2022
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015